|
|
|
|
|
|
|
||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | ||||
Development, Vol 126, Issue 19 4267-4279, Copyright © 1999 by Company of Biologists
JOURNAL ARTICLES |
E Filvaroff, A Erlebacher, J Ye, SE Gitelman, J Lotz, M Heillman and R Derynck
Department of Growth, University of California at San Francisco, San Francisco, CA 94143, USA.
Transforming growth factor-beta (TGF-beta) is abundant in bone matrix and has been shown to regulate the activity of osteoblasts and osteoclasts in vitro. To explore the role of endogenous TGF-(beta) in osteoblast function in vivo, we have inhibited osteoblastic responsiveness to TGF-beta in transgenic mice by expressing a cytoplasmically truncated type II TGF-beta receptor from the osteocalcin promoter. These transgenic mice develop an age-dependent increase in trabecular bone mass, which progresses up to the age of 6 months, due to an imbalance between bone formation and resorption during bone remodeling. Since the rate of osteoblastic bone formation was not altered, their increased trabecular bone mass is likely due to decreased bone resorption by osteoclasts. Accordingly, direct evidence of reduced osteoclast activity was found in transgenic mouse skulls, which had less cavitation and fewer mature osteoclasts relative to skulls of wild-type mice. These bone remodeling defects resulted in altered biomechanical properties. The femurs of transgenic mice were tougher, and their vertebral bodies were stiffer and stronger than those of wild-type mice. Lastly, osteocyte density was decreased in transgenic mice, suggesting that TGF-beta signaling in osteoblasts is required for normal osteoblast differentiation in vivo. Our results demonstrate that endogenous TGF-beta acts directly on osteoblasts to regulate bone remodeling, structure and biomechanical properties.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  B. A Teicher, J. M Yingling, and J. M McPherson TGF{beta} Blockade as Anticancer Therapy Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 71 - 81. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Tan, T. Weng, J. Zhang, J. Wang, W. Li, H. Wan, Y. Lan, X. Cheng, N. Hou, H. Liu, et al. Smad4 is required for maintaining normal murine postnatal bone homeostasis J. Cell Sci., July 1, 2007; 120(13): 2162 - 2170. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Sasaki, Y. Ito, P. Bringas Jr, S. Chou, M. M. Urata, H. Slavkin, and Y. Chai TGF{beta}-mediated FGF signaling is crucial for regulating cranial neural crest cell proliferation during frontal bone development Development, January 15, 2006; 133(2): 371 - 381. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Balooch, M. Balooch, R. K. Nalla, S. Schilling, E. H. Filvaroff, G. W. Marshall, S. J. Marshall, R. O. Ritchie, R. Derynck, and T. Alliston TGF-{beta} regulates the mechanical properties and composition of bone matrix PNAS, December 27, 2005; 102(52): 18813 - 18818. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Janssens, P. ten Dijke, S. Janssens, and W. Van Hul Transforming Growth Factor-{beta}1 to the Bone Endocr. Rev., October 1, 2005; 26(6): 743 - 774. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Bi, C. H. Stuelten, T. Kilts, S. Wadhwa, R. V. Iozzo, P. G. Robey, X.-D. Chen, and M. F. Young Extracellular Matrix Proteoglycans Control the Fate of Bone Marrow Stromal Cells J. Biol. Chem., August 26, 2005; 280(34): 30481 - 30489. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Colarossi, Y. Chen, H. Obata, V. Jurukovski, L. Fontana, B. Dabovic, and D. B. Rifkin Lung Alveolar Septation Defects in Ltbp-3-Null Mice Am. J. Pathol., August 1, 2005; 167(2): 419 - 428. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. B. Rifkin Latent Transforming Growth Factor-{beta} (TGF-{beta}) Binding Proteins: Orchestrators of TGF-{beta} Availability J. Biol. Chem., March 4, 2005; 280(9): 7409 - 7412. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Toyo-oka, S. Hirotsune, M. J. Gambello, Z.-Q. Zhou, L. Olson, M. G. Rosenfeld, R. Eisenman, P. Hurlin, and A. Wynshaw-Boris Loss of the Max-interacting protein Mnt in mice results in decreased viability, defective embryonic growth and craniofacial defects: relevance to Miller-Dieker syndrome Hum. Mol. Genet., May 15, 2004; 13(10): 1057 - 1067. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Karsdal, P. Hjorth, K. Henriksen, T. Kirkegaard, K. L. Nielsen, H. Lou, J.-M. Delaisse, and N. T. Foged Transforming Growth Factor-{beta} Controls Human Osteoclastogenesis through the p38 MAPK and Regulation of RANK Expression J. Biol. Chem., November 7, 2003; 278(45): 44975 - 44987. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. P. Denton, B. Zheng, L. A. Evans, X. Shi-wen, V. H. Ong, I. Fisher, K. Lazaridis, D. J. Abraham, C. M. Black, and B. de Crombrugghe Fibroblast-specific Expression of a Kinase-deficient Type II Transforming Growth Factor {beta} (TGF{beta}) Receptor Leads to Paradoxical Activation of TGF{beta} Signaling Pathways with Fibrosis in Transgenic Mice J. Biol. Chem., June 27, 2003; 278(27): 25109 - 25119. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Annes, J. S. Munger, and D. B Rifkin Making sense of latent TGF{beta} activation J. Cell Sci., January 15, 2003; 116(2): 217 - 224. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Karsdal, L. Larsen, M. T. Engsig, H. Lou, M. Ferreras, A. Lochter, J.-M. Delaisse, and N. T. Foged Matrix Metalloproteinase-dependent Activation of Latent Transforming Growth Factor-beta Controls the Conversion of Osteoblasts into Osteocytes by Blocking Osteoblast Apoptosis J. Biol. Chem., November 8, 2002; 277(46): 44061 - 44067. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Peacock, C. H. Turner, M. J. Econs, and T. Foroud Genetics of Osteoporosis Endocr. Rev., June 1, 2002; 23(3): 303 - 326. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Szweras, D. Liu, E. A. Partridge, J. Pawling, B. Sukhu, C. Clokie, W. Jahnen-Dechent, H. C. Tenenbaum, C. J. Swallow, M. D. Grynpas, et al. alpha 2-HS Glycoprotein/Fetuin, a Transforming Growth Factor-beta /Bone Morphogenetic Protein Antagonist, Regulates Postnatal Bone Growth and Remodeling J. Biol. Chem., May 24, 2002; 277(22): 19991 - 19997. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Itoh, N. Udagawa, T. Katagiri, S. Iemura, N. Ueno, H. Yasuda, K. Higashio, J. M. W. Quinn, M. T. Gillespie, T. J. Martin, et al. Bone Morphogenetic Protein 2 Stimulates Osteoclast Differentiation and Survival Supported by Receptor Activator of Nuclear Factor-{kappa}B Ligand Endocrinology, August 1, 2001; 142(8): 3656 - 3662. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Bahamonde and K. M Lyons BMP3: To Be or Not To Be a BMP J. Bone Joint Surg. Am., April 1, 2001; 83(90010): S56 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Bahamonde and K. M Lyons BMP3: To Be or Not To Be a BMP J. Bone Joint Surg. Am., March 1, 2001; 83(1_suppl_1): S56 - S62. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kaneda, T. Nojima, M. Nakagawa, A. Ogasawara, H. Kaneko, T. Sato, H. Mano, M. Kumegawa, and Y. Hakeda Endogenous Production of TGF-{beta} Is Essential for Osteoclastogenesis Induced by a Combination of Receptor Activator of NF-{kappa}B Ligand and Macrophage-Colony- Stimulating Factor J. Immunol., October 15, 2000; 165(8): 4254 - 4263. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Dabovic, Y. Chen, C. Colarossi, H. Obata, L. Zambuto, M. A. Perle, and D. B. Rifkin Bone abnormalities in latent TGF-{beta} binding protein (Ltbp)-3-null mice indicate a role for Ltbp-3 in modulating TGF-{beta} bioavailability J. Cell Biol., January 21, 2002; 156(2): 227 - 232. [Abstract] [Full Text] [PDF]
|
|
